fbpx
X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:

ESHG 2021: How HiFi Sequencing is Closing the Gaps in Rare Disease Research

Thursday, September 23, 2021

 

It’s a challenge that has haunted rare disease researchers for years: how to increase solve rates in rare and Mendelian disease. Currently, the genetic cause of more than half of rare disease cases worldwide remain unexplained.

In a series of talks and posters presented at the 2021 annual meeting of The European Society of Human Genetics (#ESHG21), PacBio experts and users described how HiFi sequencing could help close the gap by providing more comprehensive, accurate and high-definition coverage of the gaps in the human genome.

Here is a summary of the discussions that took place and the posters that were presented:

 


Long-Read Genome Sequencing for the Molecular Understanding of Rare Disease and Neurodevelopmental Disorders

 

 

In the first workshop, Susan Hiatt (@suzieqhiatt) from HudsonAlpha Institute for Biotechnology discussed how she and her team used HiFi sequencing in their rare disease research to discover genomic variation missed by whole-exome or genome sequencing studies using short reads.

PacBio’s Chief Scientific Officer Jonas Korlach also provided a summary about how advancements in sequencing technology, coupled with improved analytical tools and databases, have made it possible to finally examine hard-to-reach regions of the human genome, with huge implications for rare disease research.

 

“PacBio continues this march of technology evolution, and soon more than half, and perhaps up to two-thirds of unexplained rare disease cases can be explained through HiFi sequencing,” – Jonas Korlach

He went on to say: “We believe that high quality whole genome sequencing is the future of medicine and that this will be the first of many impactful demonstrations.”

 

Learn more about the work here.

 


Targeting Clinically Significant Dark Regions of the Human Genome with High-accuracy, Long-read Sequencing

 
ESHG Poster Targeting Clinically Significant Dark Regions of the Human Genome

In a poster presentation, researchers at PacBio showed how there are many clinically important genes in “dark” regions of the human genome. They explained how these often exist because of a paucity of NGS coverage or mapping difficulties, often complicated by the presence of various repeat elements or segmental duplications.

View the poster to see how long-read sequencing coupled with a long-PCR targeted enrichment method has the potential to illuminate these dark regions, using examples from CYP21A2, responsible for congenital adrenal hyperplasia, and GBA, responsible for Gaucher’s disease.

 


Resolving Complex Pathogenic Alleles Using HiFi Long-range Amplicon Data and a New Clustering Algorithm

 

ESHG Poster 2021 Resolving complex pathogenic alleles using HiFi long-range amplicon data and a new clustering algorithm

In another poster presentation, experts outlined how many genetic diseases are mapped to structurally complex regions containing highly similar paralogous alleles (>99% identity) that span kilobases and how, as a result, comprehensive screening for pathogenic variants is incomplete and labor intensive using short-reads or optical mapping.

View this poster to find out how long-range amplification and PacBio HiFi sequencing can fully resolve and phase a wide range of pathogenic variants with the help of a new amplicon analysis tool, pbAA.

 


Full-Length Sequencing of CYP2D6 Locus with HiFi Reads Increasing Genotypes Accuracy

 

ESHG Poster 2021 Full-length sequencing of CYP2D6 locus with HiFi reads increasing genotypes accuracy

And, in the final poster presentation, there was an insightful deep dive into personalized medicine. This poster reviews new discoveries around how the highly polymorphic CYP2D6 gene impacts the metabolism of 25% of the most prescribed drugs on the market. Experts reviewed this poster to inspire a discussion around how accurate identification of variant CYP2D6 alleles in individuals is necessary for personalized medicine.

View the poster to see how HiFi sequencing coupled with long-PCR targeted enrichment has successfully characterized 22 samples from a pharmacogenomics reference panel.

 


Comprehensive Detection of Variants in Unsolved Rare Disease Studies with PacBio HiFi Reads

 

Lastly, experts discussed how PacBio HiFi reads (99.9% accuracy, 15-25 kb) enable comprehensive variant detection in human genomes, extending to repetitive regions of the genome not accessible with short-read WGS (srWGS). It was revealed that HiFi reads match or surpass srWGS for single nucleotide variant and small indel detection while also improving detection of structural variants (SVs), with recall far exceeding that of srWGS.

This talk showcased how HiFi can be applied in a large-scale, reproducible way using an automated workflow, and how it performed on 80 rare disease cases unexplained by srWGS.

 


All in all, ESHG 2021 was full of insight, discovery and hope. With HiFi sequencing, we are excited about what the future holds.

If you would like to watch the workshop recording on demand, go here.

Or, if you’d like to learn more about highly accurate long-read sequencing and how it plays a role in human biomedical research, visit us here.

Subscribe for blog updates:

Archives

Search

Categories

Press Release

PacBio Grants Equity Incentive Award to New Employee

Friday, November 19, 2021